Corvus Pharmaceuticals

General Information

We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. Our lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint.

Employees: 33
Founded: 2014
Contact Information
Address 863 Mitten Road, Suite 102, Burlingame, CA 94010< US
Phone Number (650) 900-4520
Web Address
View Prospectus: Corvus Pharmaceuticals
Financial Information
Market Cap $306.1mil
Revenues $0.0 mil (last 12 months)
Net Income $-31.3 mil (last 12 months)
IPO Profile
Symbol CRVS
Exchange NASDAQ
Shares (millions): 4.7
Price range $15.00 - $15.00
Est. $ Volume $70.5 mil
Manager / Joint Managers Credit Suisse/ Cowen and Company
CO-Managers Guggenheim Securities/ Cantor Fitzgerald/ BTIG
Expected To Trade: 3/23/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change